Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's EV-to-FCF or its related term are showing as below:
HKSE:06833'
s EV-to-FCF Range Over the Past 10 Years
Min: -50.81 Med: 1.19 Max: 29.84
Current: 1.28
During the past 12 years, the highest EV-to-FCF of Sinco Pharmaceutical Holdings was 29.84. The lowest was -50.81. And the median was 1.19.
HKSE:06833's EV-to-FCF is ranked better than 97.06% of 68
companies
in the Medical Distribution industry
Industry Median: 17.655
vs HKSE:06833: 1.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinco Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
Sinco Pharmaceutical Holdings's share price for today is HK$0.166.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinco Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.019.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sinco Pharmaceutical Holdings EV-to-FCF Related Terms
Sinco Pharmaceutical Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's EV-to-FCF falls into.
Sinco Pharmaceutical Holdings's current Enterprise Value is HK$257 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinco Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinco Pharmaceutical Holdings (HKSE:06833) has a EV-to-FCF of 1.29 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is near median its historical median of 1.19. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #2 out of 68 companies in the Medical Distribution industry, placing it in the top 2.9%.
Is Sinco Pharmaceutical Holdings' EV-to-FCF too high?
Sinco Pharmaceutical Holdings' current EV-to-FCF of 1.29 is near median its 10-year median of 1.19. The Medical Distribution industry median EV-to-FCF is 17.66. Sinco Pharmaceutical Holdings' value of 1.29 is 92.7% below this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #2 out of 68 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #2 out of 68 companies for EV-to-FCF. This places Sinco Pharmaceutical Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.66. Sinco Pharmaceutical Holdings' value of 1.29 is 92.7% below this benchmark. While the company's 10-year median is 1.19 vs. the industry median of 17.66, Sinco Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.66, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current EV-to-FCF of 1.29 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current EV-to-FCF is 1.29, which is near median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current EV-to-FCF is 1.29, which is near median its 10-year median of 1.19 and 92.7% below the Medical Distribution industry median of 17.66. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current EV-to-FCF is 1.29 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
EV-to-FCF: 1.29 (near median its 10-year median of 1.19)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 92.7% below the Medical Distribution median (#2 of 68)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
